Hypera S.A - Asset Resilience Ratio
Hypera S.A (HYPE3) has an Asset Resilience Ratio of 5.72% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hypera S.A (HYPE3) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2025)
This chart shows how Hypera S.A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Hypera S.A's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Hypera S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore HYPE3 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | R$1.64 Billion | 5.72% |
| Short-term Investments | R$0.00 | 0% |
| Total Liquid Assets | R$1.64 Billion | 5.72% |
Asset Resilience Insights
- Limited Liquidity: Hypera S.A maintains only 5.72% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Hypera S.A Industry Peers by Asset Resilience Ratio
Compare Hypera S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Hypera S.A (2009–2025)
The table below shows the annual Asset Resilience Ratio data for Hypera S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.72% | R$1.64 Billion ≈ $320.90 Million |
R$28.59 Billion ≈ $5.61 Billion |
-1.12pp |
| 2024-12-31 | 6.84% | R$1.68 Billion ≈ $329.79 Million |
R$24.56 Billion ≈ $4.82 Billion |
-3.56pp |
| 2023-12-31 | 10.41% | R$2.55 Billion ≈ $500.42 Million |
R$24.51 Billion ≈ $4.81 Billion |
-0.83pp |
| 2022-12-31 | 11.23% | R$2.67 Billion ≈ $523.67 Million |
R$23.76 Billion ≈ $4.66 Billion |
+2.57pp |
| 2021-12-31 | 8.66% | R$1.72 Billion ≈ $336.94 Million |
R$19.82 Billion ≈ $3.89 Billion |
-13.83pp |
| 2020-12-31 | 22.49% | R$3.88 Billion ≈ $761.38 Million |
R$17.25 Billion ≈ $3.38 Billion |
+10.58pp |
| 2019-12-31 | 11.92% | R$1.42 Billion ≈ $278.77 Million |
R$11.92 Billion ≈ $2.34 Billion |
-1.53pp |
| 2018-12-31 | 13.45% | R$1.42 Billion ≈ $278.53 Million |
R$10.56 Billion ≈ $2.07 Billion |
+1.52pp |
| 2017-12-31 | 11.93% | R$1.21 Billion ≈ $237.13 Million |
R$10.13 Billion ≈ $1.99 Billion |
+2.71pp |
| 2016-12-31 | 9.22% | R$1.05 Billion ≈ $205.90 Million |
R$11.38 Billion ≈ $2.23 Billion |
+11.90pp |
| 2015-12-31 | -2.68% | R$-423.77 Million ≈ $-83.15 Million |
R$15.82 Billion ≈ $3.10 Billion |
-0.50pp |
| 2014-12-31 | -2.17% | R$-301.92 Million ≈ $-59.24 Million |
R$13.89 Billion ≈ $2.73 Billion |
-1.52pp |
| 2013-12-31 | -0.65% | R$-81.63 Million ≈ $-16.02 Million |
R$12.50 Billion ≈ $2.45 Billion |
-0.04pp |
| 2012-12-31 | -0.62% | R$-78.00 Million ≈ $-15.31 Million |
R$12.66 Billion ≈ $2.48 Billion |
-0.63pp |
| 2011-12-31 | 0.01% | R$1.71 Million ≈ $335.93K |
R$13.33 Billion ≈ $2.61 Billion |
+0.35pp |
| 2010-12-31 | -0.34% | R$-33.87 Million ≈ $-6.65 Million |
R$9.99 Billion ≈ $1.96 Billion |
-0.22pp |
| 2009-12-31 | -0.12% | R$-7.28 Million ≈ $-1.43 Million |
R$6.09 Billion ≈ $1.20 Billion |
-- |
About Hypera S.A
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Co… Read more